New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
Posted by rob on February 5, 2011 under Uncategorized | 
Comments are off for this article
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
Invest New Drugs. 2010 Dec;28(6):876-8
Authors: Santucci MA, Mancini M, Corradi V, Lacobucci I, Martinelli G, Botta M, Schenone S
PMID: 19629392 [PubMed - indexed for MEDLINE]